- Stocks
- Pharma & Healthcare
- Deccan Health C
Deccan Health C share price
NSE: DECCANPharma & HealthcareDrug Manufacturers - Specialty & Generic
Deccan Health C at a glance
With a market capitalisation of ₹32 Cr, it ranks 3335th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 2.3% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹21 Cr (+1.1% year on year) and net profit ₹0 Cr (+175.0%), on a consolidated basis. Promoters held 19.46% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹32 CrRank 3335 on NSE
- Price to book
- 0.15×FY26
- EPS (TTM)
- ₹1.02to Q4 FY26
- ROE
- 2.3%FY26
- ROCE
- 3.2%FY26
- Debt to equity
- 0.04FY26
- Net profit margin
- 3.0%FY26
- Book value / share
- ₹44.55FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Deccan Health C quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹13 Cr | ₹19 Cr | ₹20 Cr | ₹21 Cr | ₹22 Cr | ₹21 Cr | ₹17 Cr | ₹21 Cr |
| Revenue YoY | +17.3% | +9.5% | +33.2% | +29.9% | +67.9% | +13.7% | −14.9% | +1.1% |
| Net profit | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr |
| Net profit YoY | +20.0% | −1.9% | −73.6% | −7.7% | −33.3% | +71.7% | +614.3% | +175.0% |
| Net margin | 2.7% | 2.8% | 0.7% | 0.6% | 1.1% | 4.3% | 5.8% | 1.6% |
| EPS | ₹0.18 | ₹0.26 | ₹0.07 | ₹0.05 | ₹0.10 | ₹0.37 | ₹0.41 | ₹0.14 |
Deccan Health C financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹34 Cr | ₹33 Cr | ₹45 Cr | ₹60 Cr | ₹75 Cr | — |
| Operating profit | ₹1 Cr | ₹4 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | — |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | — |
| EPS (₹) | ₹0.00 | ₹0.00 | ₹0.00 | ₹1.00 | ₹1.00 | — |
| Cash from operations | ₹0 Cr | −₹1 Cr | −₹7 Cr | −₹13 Cr | −₹6 Cr | — |
| Total debt | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹3 Cr |
| Shareholders' equity | ₹77 Cr | ₹77 Cr | ₹82 Cr | ₹97 Cr | ₹106 Cr | ₹110 Cr |
Deccan Health C shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 19.46% | 18.42% | 18.42% | 18.42% | 19.46% | 19.46% |
| Domestic institutions | 5.68% | 5.37% | 5.37% | 5.37% | 5.68% | 5.68% |
| Non-institutions | 74.86% | 76.21% | 76.21% | 76.21% | 74.86% | 74.86% |
Deccan Health C vs peers
The listed Pharma & Healthcare companies nearest to Deccan Health C by market capitalisation.
Ask anything about Deccan Health C
Pivot answers on the live chart with evidence you can check, and tests strategies against DECCAN's own history. Try: “Why has DECCAN moved over the last three months?” · “Backtest a 50-day moving-average crossover on DECCAN over five years” · “Compare DECCAN with JFLLIFE on margins and valuation”
Frequently asked questions about Deccan Health C
What is the market cap of Deccan Health C?
Deccan Health C's market capitalisation is ₹32 Cr (₹32 Cr) at the 22 Oct 2026 close, ranking 3335th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Deccan Health C?
Return on equity was 2.3% in FY26 and return on capital employed was 3.2% in FY26 (consolidated figures).
Is Deccan Health C a debt-free company?
Deccan Health C is close to debt-free: its debt-to-equity ratio was 0.04 in FY26.
What were Deccan Health C's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Deccan Health C reported revenue of ₹21 Cr, +1.1% year on year, and net profit of ₹0 Cr, +175.0% year on year.
What is the shareholding pattern of Deccan Health C?
As of 30 Jun 2026: promoters 19.46%, domestic institutions 5.68%, non-institutions 74.86%.
Who are Deccan Health C's competitors?
The listed Pharma & Healthcare companies closest to Deccan Health C by market cap are JFL Life Scienc, Chandra Bhagat, Sharma East Ind, Medi-Caps, KK Shah Hospita and Panjon.
Is Deccan Health C a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Deccan Health C's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DECCAN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text